Skip to main content

Advertisement

Fig. 7 | Cell & Bioscience

Fig. 7

From: Kv1.3 channel blocker (ImKTx88) maintains blood–brain barrier in experimental autoimmune encephalomyelitis

Fig. 7

ImKTx88 treatment decreases IL-17 expression in vivo and in vitro. a mRNA levels of IL-17 from the control group, EAE group, ImKTx88 prevention group and ImKTx88 treatment group (n = 8) were analyzed by qRT-PCR. b IL-17 expression was analyzed via ELISA. EAE induction significantly increased the levels of IL-17 in the cerebellum, and ImKTx88 inhibited the increase in IL-17. c PBMCs were pretreated with ImKTx88 (100 nM, 1 and 10 μM) for 60 min and then stimulated with Con A (100 μg/ml) for 24 h. After treatment, IL-17 was detected in culture medium using ELISA. Compared with Con A stimulated cells, the PBMCs pretreated with ImKTx88 showed low expression of IL-17. Data represent the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page